Literature DB >> 3565280

Left ventricular systolic and diastolic flow abnormalities determined by Doppler echocardiography in obstructive hypertrophic cardiomyopathy.

R J Bryg, A C Pearson, G A Williams, A J Labovitz.   

Abstract

To analyze the relation of systolic anterior motion (SAM) of the mitral valve, peak left ventricular (LV) outflow tract velocity, aortic flow and mitral flow, 17 patients with obstructive hypertrophic cardiomyopathy (HC) (8 men, 9 women), aged 19 to 88 years (mean 45), were studied using M-mode and 2-dimensional echocardiography and pulsed and continuous-wave Doppler echocardiography and results were compared with those from 18 age-matched normal subjects. SAM was present in all patients with HC and absent in normal subjects. Time to peak outflow velocity as a percentage of LV ejection time was 63% in patients with HC and 29% in normal subjects (p less than 0.001). In 13 patients, time from the R-wave peak to the closest approximation of the mitral valve to the ventricular septum or initial contact during SAM was determined and was 242 +/- 66 ms and time from the R-wave peak to the peak LV outflow tract velocity was 242 +/- 73 ms (r = 0.90). In 11 patients time from the R-wave peak to cessation of flow in the ascending aorta was measured and was 286 +/- 80 ms; time from the R-wave peak to the peak LV outflow tract velocity was 246 +/- 75 ms. The ratio of early to late diastolic filling velocities of the left ventricle was 1.47 +/- 0.40 in the normal subjects and 1.26 +/- 0.84 in patients with HC (difference not significant). The early to late ratio of the 12 patients without mitral regurgitation was 0.99 +/- 0.52 (p less than 0.01 vs normal subjects).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1987        PMID: 3565280     DOI: 10.1016/0002-9149(87)91127-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Pulsed Doppler assessment of left ventricular diastolic function in atrial septal defect.

Authors:  B Stojnic; Z Krajcer; P Pavlovic; M Nozic; R Aleksandrov; M Prcovic
Journal:  Tex Heart Inst J       Date:  1992

2.  Characteristics of left ventricular filling in coronary artery disease and myocardial ischaemia after dipyridamole provocation.

Authors:  M Shahi; A Nadazdin; R A Foale
Journal:  Br Heart J       Date:  1991-05

3.  Right ventricular and pulmonary function in sickle cell disease patients with pulmonary hypertension.

Authors:  Ferit Akgül; Fatih Yalçin; Cenk Babayiğit; Ergün Seyfeli; Tunzale Seydaliyeva; Edip Gali
Journal:  Pediatr Cardiol       Date:  2006-07-11       Impact factor: 1.655

4.  Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Tai Sekine; Masao Daimon; Rei Hasegawa; Kiyomi Teramoto; Takayuki Kawata; Nobuhiro Tanaka; Yasuhiro Takei; Kenji Takazawa; Katsuya Yoshida; Issei Komuro
Journal:  Heart Vessels       Date:  2006-11-27       Impact factor: 2.037

5.  Acute alterations of pre- and afterload: are Doppler-derived diastolic filling patterns able to differentiate the loading condition?

Authors:  H Völler; A Uhrig; C Spielberg; H von Ameln; K Schröder; T Brüggemann; R Schröder
Journal:  Int J Card Imaging       Date:  1993-12

6.  Usefulness of Doppler echocardiographic assessment of diastolic filling in distinguishing "athlete's heart" from hypertrophic cardiomyopathy.

Authors:  J F Lewis; P Spirito; A Pelliccia; B J Maron
Journal:  Br Heart J       Date:  1992-09

7.  Myocardial performance index for detection of subclinical abnormalities in patients with sarcoidosis.

Authors:  Mehmet Gungor Kaya; Zuhal Simsek; Bahadir Sarli; Hakan Buyukoglan
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

8.  Impact of cibenzoline treatment on left ventricular remodelling and prognosis in hypertrophic obstructive cardiomyopathy.

Authors:  Mareomi Hamada; Yuji Shigematsu; Shuntaro Ikeda; Kiyotaka Ohshima; Akiyoshi Ogimoto
Journal:  ESC Heart Fail       Date:  2021-10-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.